ArticleDiscover oncology2025
Gene mutations and differentiation in laryngeal and pharyngeal squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo explore the characteristics of genomic variation patterns in Chinese patients with laryngeal and pharyngeal squamous cell carcinoma (SCC) and their correlation with differentiation and clinical significance.
methodsWe analyzed genomic variations in 45 patients. Mutation patterns were evaluated using the 688 panel. We evaluated the correlation among degree of differentiation, patient prognosis, and mutation status and also analyzed 564 HNSCC samples from the UALCAN database.
resultsSignificant differences were observed in overall survival (OS) and progression-free survival (PFS) among patients with different degrees of differentiation. Based on the DriverML model, we found that the genes with the highest mutation rates were neurogenic locus notch homolog protein 1 (NOTCH1), tumor protein 53 (TP53), FAT atypical cadherin 1 (FAT1), and mitogen-activated protein kinase kinase kinase 4 (MAP3 K4) (over 30%). We are the first to our knowledge to propose that MAP3 K4 (33%) may be a driving gene for Chinese SCC patients. Moreover, NOTCH1 and CUB and sushi multiple domains 3 (CSMD3) were mutually exclusive (p < 0.05). CSMD3 mutations were primarily found in poorly differentiated patients (83%, 5/6). Furthermore, NOTCH1
conclusionWe identified a potential new driving gene, MAP3 K4, in Chinese SCC patients and confirmed that the interaction between NOTCH1-MAP3 K4 may affect the differentiation of laryngeal and pharyngeal SCC. However, further exploration and large-scale sample validation are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.